Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease. (May 2022)

• Record Type: Journal Article
• Authors: Nishijima, Haruo; Mori, Fumiaki; Kimura, Tamaki; Miki, Yasuo; Kinoshita, Iku; Nakamura, Takashi; Kon, Tomoya; Suzuki, Chieko; Wakabayashi, Koichi; Tomiyama, Masahiko
• Is Part Of: Neuroscience research. Volume 178(2022)
• Page Start: 93
• Page End: 97
• Publication Date: 2022-05
• Subjects: 6-OHDA 6-hydroxydopamine -- AIM abnormal involuntary movement -- ALO AIM score the sum of the axial, forelimb, and orolingual scores -- CDS continuous dopaminergic stimulation -- GABA gamma-aminobutyric acid -- GPi the internal segment of globus pallidus -- LCIG L-dopa-carbidopa continuous infusion gel -- L-dopa Levo-dihydroxyphenylalanine -- LID L-dopa-induced dyskinesia -- mRNA messenger ribonucleic acid -- PD Parkinson's disease -- SPN spiny projection neuron; 6-hydroxydopamine -- Abnormal involuntary movement -- Continuous dopaminergic stimulation -- Dynorphin -- Entopeduncular nucleus -- Globus pallidus internus; Neurosciences -- Research -- Periodicals; Neurosciences -- Research -- Japan -- Periodicals; Neurology -- Periodicals; Neurosciences -- Periodicals; Neurosciences -- Recherche -- Périodiques; Neurosciences -- Recherche -- Japon -- Périodiques; Neurosciences -- Research; Japan; Periodicals; 612.8
• DOI: 10.1016/j.neures.2022.02.001
• Languages: English
• ISSNs: 0168-0102

Abstract

Abstract: Intermittent administration of L -dopa in Parkinson's disease is associated with L -dopa-induced dyskinesia (LID). Long-acting dopamine agonists may reduce the risk of LID by continuous dopaminergic stimulation. We examined the LID-like behavior, preprodynorphin messenger ribonucleic acid (mRNA) expression in the striatum (a neurochemical LID hallmark), and the volume of the entopeduncular nucleus (a pathological LID hallmark) in Parkinson's disease rat models that were treated with L -dopa and cabergoline. Cabergoline co-treatment with L -dopa reduced LID, striatal preprodynorphin mRNA expression, and hypertrophy of the entopeduncular nucleus, indicating that cabergoline has an anti-LID effect independent of the L -dopa-sparing effect. Highlights: Cabergoline is a long-acting dopamine agonist. Cabergoline co-treatment with L -dopa reduced L -dopa-induced dyskinesia in model rats. Cabergoline co-treatment decreased striatal preprodynorphin mRNA expression. Cabergoline co-treatment suppressed hypertrophy of the entopeduncular nucleus. Cabergoline has an anti-dyskinesia effect independent of the L -dopa-sparing effect.